36776-44-0

Upstream product

• 504-15-4 orcinol 
• 100-39-0 benzyl bromide 
• 6153-39-5 5-Methylresorcinol monohydrate 

Downstream Products

• 33716-85-7 2,3'-bis(benzyloxy)-5',6-dimethyl-4-methoxydiphenyl ether 
• 850793-46-3 C₂₁H₁₆BrF₃O₂ 
• 208643-33-8 3-[(3-benzyloxy-5-methyl)phenoxy]propanol 
• 197959-63-0 2-(3-benzyloxy-5-methyl)phenoxy-2-methylpropanamide 
• 34883-10-8 4-(benzyloxy)-2-hydroxy-6-methylbenzaldehyde 
• 850793-05-4 3-[4-(3-benzyloxy-5-methyl-phenoxy)-2-methyl-phenyl]acrylic acid ethyl ester 

Relevant academic research and scientific papers

HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R9, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

AMIDINOHYDRAZONES AS PROTEASE INHIBITORS

Amidino and benzamidino compounds, including compounds of the formula: I wherein R1-R4, R6-R9, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I.

PHENOXYETHER DERIVATIVES AS PPAR MODULATORS

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR), such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

Aminoguanidines and alkoxyguanidines as protease inhibitors

Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: wherein X is O or NR9and R114 R4, R6-R9, R11, R12, Ra, Rb, Rc, Y, Z, n and mare set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

AMIDINOHYDRAZONES AS PROTEASE INHIBITORS

Amidino and benzamidino compounds, including compounds of the formula: STR1 wherein R 1-R 4, R 6-R 9, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I.

GUANIDINO PROTEASE INHIBITORS

Compounds of the formula: STR1 wherein R 1--R 4, R. sup.7--R 8, R a, R b, R c, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit a number of proteolytic enzymes are described. Also described are methods for preparing the compounds of Formula I.

SYNTHESIS AND HERBICIDAL ACTIVITY OF CYPERIN

Cyperin is a phytotoxic diphenyl ether natural product.Total synthesis of cyperin has been achieved and its herbicidal activity evaluated.The synthesis is highlighted by an Ullmann coupling to construct the diphenyl ether moiety contained within cyperin.I